<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Trousseau's syndrom may be defined as a symptomatic state of venous and/or arterial <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo> in patients with known or undiscovered <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It represents a clinical continuum from a subclinical prothrombotic state to <z:hpo ids='HP_0005521'>disseminated intravascular coagulation</z:hpo> (<z:chebi fb="0" ids="53092">DIC</z:chebi>), venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (VTE) and non-<z:mp ids='MP_0001794'>bacterial</z:mp> thrombotic <z:hpo ids='HP_0100584'>endocarditis</z:hpo> (NBTE) </plain></SENT>
<SENT sid="2" pm="."><plain>MATERIAL AND METHODS: A 58-year-old woman with bilateral <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> and ischemic infarctions of the heart, brain, liver and kidneys is presented </plain></SENT>
<SENT sid="3" pm="."><plain>Literature published before November 2005 was retrieved from a systematic MEDLINE search </plain></SENT>
<SENT sid="4" pm="."><plain>The case is discussed in the light of relevant literature </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS AND INTERPRETATION: Our patient developed Trousseau's syndrom due to a mucinous ventricular <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> should be used as treatment and secondary prophylaxis in patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and VTE </plain></SENT>
<SENT sid="7" pm="."><plain>Dalteparin reduces the risk of <z:hpo ids='HP_0004831'>recurrent thromboembolism</z:hpo> more effectively than <z:chebi fb="2" ids="28794">coumarin</z:chebi> derivatives, and it is not associated with a greater risk of <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>It may improve survival in patients with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumours</z:e> without <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>There is no consensus regarding treatment of patients with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:chebi fb="0" ids="53092">DIC</z:chebi>/NBTE, but dalteparin may be an option </plain></SENT>
</text></document>